Genetics-driven precision medicines for severe rare diseases
Setara Biosciences is a San Diego clinical-stage biotechnology company using human genetics to develop precision medicines for severe rare diseases. It was formed after Jazz Pharmaceuticals acquired Actio Biosciences and is advancing Actio's remaining pipeline, led by STAR-0871, an oral small-molecule TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C and overactive bladder, plus earlier discovery programs. In October 2026 it announced a $90 million Series A from investors including Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures and Jazz Pharmaceuticals.